

1Q 2015 - Performance Summary

GRIFOLS | 75
ANNIVERSARY

Operational and Financial Highlights - 1Q 2015

- Net profit up by +6.2% to Euros 128.5 million
- Income grows by +13.8% (+1.1% cc*) to Euros 908.4 million, driven by sales of alpha-1 antitrypsin, one of the main plasma proteins (Bioscience division) and by NAT technology diagnostic solutions (Diagnostic division)
- The company consolidates its geographical expansion: sales in regions other than the United States and Canada and the European Union (Rest of the World – R.O.W.) up by +17.8% (+6.9% cc)
- EBITDA grows +3.6% reaching Euros 280 million
- EBITDA margin at 30.8% of income, despite the significant investment in R&D that increased by +34.4% to Euros 50.9 million. Additional R&D investments of Euros 8 million were made through investees during this quarter
- EBIT grows 5.6% to Euros 236.4 million

Operational and Financial Highlights - 1Q 2015

- Net financial debt of Euros 3,981 million, a ratio of 3.7 times EBITDA (3.3x cc) including cash of Euros 800 million. Additionally, Euros 400 million of undrawn facilities are available
- Strengthened R&D portfolio with the acquisition of 47.58% of the capital of Alkahest

** Constant currency (cc) excludes the impact of exchange rate movements*

Key financial figures - 1Q 2015

<i>In millions of euros except % and EPS</i>	1Q 2015	1Q 2014	% Var
NET REVENUE (NR)	908.4	798.0	13.8%
GROSS PROFIT	49.7%	52.7%	
R&D	50.9	37.9	34.4%
% NR	5.6%	4.7%	
EBITDA	280.0	270.2	3.6%
% NR	30.8%	33.9%	
EBIT	236.4	223.9	5.6%
% NR	26.0%	28.1%	
GROUP NET PROFIT	128.5	121.0	6.2%
% NR	14.1%	15.2%	
ADJUSTED⁽¹⁾ GROUP NET PROFIT	148.7	147.0	1.1%
% NR	16.4%	18.4%	
CAPEX	68.3	45.7	49.4%
EARNINGS PER SHARE (EPS)	0.38	0.35	8.6%

	March 2015	December 2014	% Var
TOTAL ASSETS	9,375.2	8,449.8	11.0%
TOTAL EQUITY	3,135.3	2,662.9	17.7%
CASH & CASH EQUIVALENTS	797.8	1,079.2	(26.1)%
LEVERAGE RATIO	3,7 / 3,3 (cc)⁽²⁾	3.0	

⁽¹⁾ Excludes non-recurring costs and associated with recent acquisitions, amortization of deferred expenses associated to the refinancing and amortization of intangible assets related to acquisitions

⁽²⁾ Constant currency (cc) excludes the impact of exchange rate movements

Net revenue by division - 1Q 2015

<i>In thousands of euros</i>	1Q 2015	% of Net Revenues	1Q 2014	% of Net Revenues	% Var	% Var cc*
BIOSCIENCE	681,027	75.0%	600,958	75.3%	13.3%	0.0%
DIAGNOSTIC	172,561	19.0%	146,549	18.4%	17.7%	6.0%
HOSPITAL	23,259	2.5%	24,262	3.0%	(4.1%)	(5.2%)
RAW MATERIALS AND OTHERS	31,537	3.5%	26,229	3.3%	20.2%	5.1%
TOTAL	908,384	100.0%	797,998	100.0%	13.8%	1.1%

* Constant currency (cc) excludes the impact of exchange rate movements

Net revenue by region - 1Q 2015

<i>In thousands of euros</i>	1Q 2015	% of Net Revenues	1Q 2014	% of Net Revenues	% Var	% Var cc*
US + CANADA	567,112	62.4%	484,804	60.7%	17.0%	0.2%
EU	170,997	18.8%	169,180	21.2%	1.1%	(0.7%)
R.O.W.	138,738	15.3%	117,785	14.8%	17.8%	6.9%
SUBTOTAL	876,847	96.5%	771,769	96.7%	13.6%	1.0%
RAW MATERIALS AND OTHERS	31,537	3.5%	26,229	3.3%	20.2%	5.1%
TOTAL	908,384	100.0%	797,998	100.0%	13.8%	1.1%

* Constant currency (cc) excludes the impact of exchange rate movements

Profit & Loss account - 1Q 2015

<i>In thousands of euros</i>	1Q 2015	1Q 2014	% Var
NET REVENUE (NR)	908,384	797,998	13.8%
COST OF SALES	(457,282)	(377,283)	21.2%
GROSS PROFIT	451,102	420,715	7.2%
% NR	49.7%	52.7%	
R&D	(50,916)	(37,895)	34.4%
SG&A	(163,825)	(158,956)	3.1%
<i>OPERATING EXPENSES</i>	<i>(214,741)</i>	<i>(196,851)</i>	<i>9.1%</i>
OPERATING RESULT (EBIT)	236,361	223,864	5.6%
% NR	26.0%	28.1%	
<i>FINANCIAL RESULTS</i>	<i>(74,246)</i>	<i>(66,914)</i>	<i>11.0%</i>
SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES	(315)	(1,580)	(80.1%)
PROFIT BEFORE TAX	161,800	155,370	4.1%
% NR	17.8%	19.5%	
INCOME TAX EXPENSE	(33,978)	(35,735)	(4.9%)
<i>% OF PRE-TAX INCOME</i>	<i>21.0%</i>	<i>23.0%</i>	
CONSOLIDATED PROFIT FOR THE YEAR	127,822	119,635	6.8%
RESULT ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	(668)	(1,338)	(50.0%)
GROUP PROFIT FOR THE PERIOD	128,490	120,973	6.2%
% NR	14.1%	15.2%	

Balance sheet (Assets) - 1Q 2015

<i>In thousands of euros</i>	March 2015	December 2014
NON-CURRENT ASSETS	6,550,428	5,536,627
GOODWILL AND OTHER INTANGIBLE ASSETS	4,768,296	4,243,093
PROPERTY PLANT & EQUIPMENT	1,575,917	1,147,782
INVESTMENTS IN EQUITY ACCOUNTED INVESTEEES	90,250	54,296
NON-CURRENT FINANCIAL ASSETS	33,930	9,011
OTHER NON-CURRENT ASSETS	82,035	82,445
CURRENT ASSETS	2,824,727	2,913,122
INVENTORIES	1,371,242	1,194,057
TRADE AND OTHER RECEIVABLES	623,945	615,748
OTHER CURRENT FINANCIAL ASSETS	690	502
OTHER CURRENT ASSETS	31,075	23,669
CASH AND CASH EQUIVALENTS	797,775	1,079,146
TOTAL ASSETS	9,375,155	8,449,749

Balance sheet (Equity & Liabilities) - 1Q 2015

<i>In thousands of euros</i>	March 2015	December 2014
EQUITY	3,135,300	2,662,888
CAPITAL	119,604	119,604
SHARE PREMIUM RESERVE	910,728	910,728
RESERVES	1,558,605	1,088,337
TREASURY STOCK	(69,252)	(69,252)
INTERIM DIVIDENDS	(85,944)	(85,944)
CURRENT YEAR EARNINGS	128,490	470,253
OTHER COMPREHENSIVE INCOME	568,862	224,397
NON-CONTROLLING INTERESTS	4,207	4,765
NON-CURRENT LIABILITIES	5,239,607	4,707,150
NON-CURRENT FINANCIAL LIABILITIES	4,622,148	4,154,630
OTHER NON-CURRENT LIABILITIES	617,459	552,520
CURRENT LIABILITIES	1,000,248	1,079,711
CURRENT FINANCIAL LIABILITIES	189,577	194,726
OTHER CURRENT LIABILITIES	810,671	884,985
TOTAL EQUITY AND LIABILITIES	9,375,155	8,449,749

Cash flow - 1Q 2015


<i>In thousands of euros</i>	1Q 2015	1Q 2014
GROUP PROFIT	128,490	120,973
DEPRECIATION AND AMORTIZATION	43,663	46,354
NET PROVISIONS	(4,965)	(196)
OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL	(36,125)	21,035
CHANGES IN INVENTORIES	(39,195)	(11,339)
CHANGES IN TRADE RECEIVABLES	48,767	(116,479)
CHANGES IN TRADE PAYABLES	(106,510)	64,519
<i>CHANGE IN OPERATING WORKING CAPITAL</i>	<i>(96,938)</i>	<i>(63,299)</i>
NET CASH FLOW FROM OPERATING ACTIVITIES	34,125	124,867
BUSINESS COMBINATIONS AND INVESTMENTS IN GROUP COMPANIES	(58,040)	(1,211,316)
CAPEX	(68,276)	(45,708)
R&D/OTHER INTANGIBLE ASSETS	(9,036)	(4,614)
OTHER CASH INFLOW / (OUTFLOW)	(266,667)	(1,442)
NET CASH FLOW FROM INVESTING ACTIVITIES	(402,019)	(1,263,080)
<i>FREE CASH FLOW</i>	<i>(367,894)</i>	<i>(1,138,213)</i>
ISSUE (REPAYMENT) OF DEBT	(29,442)	1,281,365
OTHER CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES	(11,334)	(167,124)
NET CASH FLOW FROM FINANCING ACTIVITIES	(40,776)	1,114,241
TOTAL CASH FLOW	(408,670)	(23,972)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	1,079,146	708,777
EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS	127,299	(208)
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	797,775	684,597

Share Performance - 1Q 2015

GRIFOLS' DAILY SHARE PRICE, CLASS A & CLASS B vs IBEX 35

BASE 100, from December 31, 2014 to March 31, 2015

Source: Infobolsa



Disclaimer

The facts and figures contained in this report which do not refer to historical data are “projections and forward looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “estimate”, “future” and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law. This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.